Related Experiment Video
Updated: May 30, 2026

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
Thioredoxin-interacting protein suppresses bladder carcinogenesis.
Koji Nishizawa1, Hiroyuki Nishiyama, Yoshiyuki Matsui
1Department of Urology, Graduate School of Medicine, Kyoto University, Sakyo-ku, Kyoto, Japan. nishizaw@kuhp.kyoto-u.ac.jp
Thioredoxin-interacting protein (TXNIP) loss accelerates bladder cancer by enhancing SDF-1/CXCR4 signaling and ERK activation. Restoring TXNIP function may offer a new therapeutic strategy for bladder cancer prevention and treatment.
Area of Science:
- Oncology
- Molecular Biology
- Cell Signaling
Background:
- Thioredoxin-interacting protein (TXNIP) exhibits tumor-suppressive functions and is often underexpressed in human cancers.
- The in vivo role of TXNIP in carcinogenesis, particularly in bladder cancer, remains incompletely understood.
- TXNIP downregulation correlates with bladder cancer grade and stage.
Purpose of the Study:
- To investigate the role of TXNIP in bladder carcinogenesis in vivo.
- To elucidate the molecular mechanisms by which TXNIP influences bladder cancer development.
- To identify potential therapeutic targets for bladder cancer based on TXNIP's function.
Main Methods:
- Utilized a mouse model of N-butyl-N-(4-hydroxybutyl) nitrosamine (BBN)-induced bladder cancer, comparing wild-type (WT) and Txnip knockout (KO) mice.
- Assessed bladder tumor incidence and progression at week 8 of BBN administration.
- Examined the expression of phospho-extracellular signal-regulated kinase (pERK), C-X-C chemokine receptor type 4 (CXCR4), and its ligand stromal cell-derived factor-1 (SDF-1) using immunohistochemistry.
- Investigated the effect of TXNIP overexpression on ERK activation in human bladder cancer cells stimulated with growth factors.
- Evaluated the therapeutic potential of a CXCR4 antagonist (TF14016) in vivo.
Main Results:
- Txnip knockout mice exhibited 100% bladder cancer incidence by week 8 of BBN administration, compared to 22% in WT mice.
- Loss of TXNIP expression led to enhanced phospho-extracellular signal-regulated kinase (pERK) expression during bladder carcinogenesis.
- TXNIP overexpression attenuated pERK expression induced by SDF-1, but not by EGF or IGF-1, in human bladder cancer cells.
- Txnip-KO mice showed increased expression of CXCR4 and pERK in urothelial cells during BBN-induced carcinogenesis.
- Administration of a CXCR4 antagonist suppressed pERK activation and inhibited bladder carcinogenesis in mice.
Conclusions:
- TXNIP negatively regulates bladder carcinogenesis by attenuating SDF-1/CXCR4-induced ERK activation.
- The SDF-1/CXCR4/ERK signaling pathway is a critical mediator of TXNIP's tumor-suppressive function in the bladder.
- Targeting the SDF-1/CXCR4 pathway presents a promising strategy for preventing or treating bladder cancer.
Related Concept Videos
Abnormal Proliferation
The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
TGF - β Signaling Pathway
The Intrinsic Apoptotic Pathway
Loss of Tumor Suppressor Gene Functions
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
